News & Updates

Undergoing a minimally invasive radical hysterectomy leads to worse survival outcomes compared with open surgery in patients with early cervical cancer, according to final results of the LACC trial presented at SGO 2022.

Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.

In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.

A history of infertility among women appears to contribute to an increased risk of incident heart failure (HF), reveals a recent study.

Women who consume foods with greater inflammation potential in high amounts are more likely to have polycystic ovary syndrome (PCOS), a study has found.

Maintenance treatment with selinexor improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer who had previously received first-line chemotherapy, particularly those with endometrioid histology and wild-type p53, according to a study presented at SGO 2022.